|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1999-9-23
|
|
pubmed:abstractText |
Active targeting of doxorubicin to macrophages was studied by incorporating it in mannose-coated liposomes by use of visceral leishmaniasis in BALB/c mice as the model macrophage disease. Mannosylated liposomal doxorubicin was more effective than liposomal doxorubicin or free doxorubicin. Because leishmaniasis is accompanied by immunosuppression, immunostimulation by interferon (IFN)-gamma was evaluated to act synergistically with mannosylated liposomal doxorubicin therapy. Combination chemotherapy with a suboptimal dose of IFN-gamma resulted in possibly complete elimination of spleen parasite burden. Analysis of mRNA levels of infected spleen cells suggested that targeted drug treatment together with IFN-gamma, in addition to greatly reducing parasite numbers, resulted in reduced levels of interleukin (IL)-4 but increased levels of IL-12 and inducible nitric oxide synthase. Such combination chemotherapy may provide a promising alternative for the cure of leishmaniasis, with a plausible conversion of antiparasitic T cell response from a Th2 to Th1 pattern indicative of long-term resistance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoxanthine...,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-4,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/NOS2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Nos2 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
180
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
811-20
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10438370-Animals,
pubmed-meshheading:10438370-Cytokines,
pubmed-meshheading:10438370-Doxorubicin,
pubmed-meshheading:10438370-Drug Carriers,
pubmed-meshheading:10438370-Drug Synergism,
pubmed-meshheading:10438370-Humans,
pubmed-meshheading:10438370-Hypoxanthine Phosphoribosyltransferase,
pubmed-meshheading:10438370-Interferon-gamma,
pubmed-meshheading:10438370-Interleukin-12,
pubmed-meshheading:10438370-Interleukin-4,
pubmed-meshheading:10438370-Leishmania donovani,
pubmed-meshheading:10438370-Leishmaniasis, Visceral,
pubmed-meshheading:10438370-Liposomes,
pubmed-meshheading:10438370-Macrophages,
pubmed-meshheading:10438370-Mice,
pubmed-meshheading:10438370-Mice, Inbred BALB C,
pubmed-meshheading:10438370-Nitric Oxide Synthase,
pubmed-meshheading:10438370-Nitric Oxide Synthase Type II,
pubmed-meshheading:10438370-Recombinant Proteins,
pubmed-meshheading:10438370-Spleen,
pubmed-meshheading:10438370-Transcription, Genetic
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis.
|
|
pubmed:affiliation |
Department of Molecular Cell Biology, Indian Institute of Chemical Biology, Calcutta, India.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
